The global market for Prostate Cancer Diagnostics was estimated to be worth US$ 13430 million in 2023 and is forecast to a readjusted size of US$ 22860 million by 2030 with a CAGR of 7.8% during the forecast period 2024-2030

Prostate Cancer Diagnostics - Market

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.

Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.

Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Prostate Cancer Diagnostics by region & country, by Type, and by Application.

The Prostate Cancer Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Diagnostics.

Market Segmentation

Scope of Prostate Cancer Diagnostics - Market Report

Report Metric	Details
Report Name	Prostate Cancer Diagnostics - Market
Forecasted market size in 2030	US$ 22860 million
CAGR	7.8%
Forecasted years	2024 - 2030
Segment by Type:	Tumor Biomarker Tests Imaging Biopsy Other
Segment by Application	Age Below 55 Age 55-75 Age Above 75
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health, DiaSorin, Myriad Genetics, Ambry Genetics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Prostate Cancer Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Prostate Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Prostate Cancer Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Prostate Cancer Diagnostics - Market size in 2030?

Ans: The Prostate Cancer Diagnostics - Market size in 2030 will be US$ 22860 million.

What is the Prostate Cancer Diagnostics - Market share by region?

Ans: North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.

Who are the main players in the Prostate Cancer Diagnostics - Market report?

Ans: The main players in the Prostate Cancer Diagnostics - Market are OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health, DiaSorin, Myriad Genetics, Ambry Genetics

What are the Application segmentation covered in the Prostate Cancer Diagnostics - Market report?

Ans: The Applications covered in the Prostate Cancer Diagnostics - Market report are Age Below 55, Age 55-75, Age Above 75

What are the Type segmentation covered in the Prostate Cancer Diagnostics - Market report?

Ans: The Types covered in the Prostate Cancer Diagnostics - Market report are Tumor Biomarker Tests, Imaging, Biopsy, Other

1 Market Overview

1.1 Prostate Cancer Diagnostics Product Introduction

1.2 Global Prostate Cancer Diagnostics Market Size Forecast

1.3 Prostate Cancer Diagnostics Market Trends & Drivers

1.3.1 Prostate Cancer Diagnostics Industry Trends

1.3.2 Prostate Cancer Diagnostics Market Drivers & Opportunity

1.3.3 Prostate Cancer Diagnostics Market Challenges

1.3.4 Prostate Cancer Diagnostics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Prostate Cancer Diagnostics Players Revenue Ranking (2023)

2.2 Global Prostate Cancer Diagnostics Revenue by Company (2019-2024)

2.3 Key Companies Prostate Cancer Diagnostics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Prostate Cancer Diagnostics Product Offered

2.5 Key Companies Time to Begin Mass Production of Prostate Cancer Diagnostics

2.6 Prostate Cancer Diagnostics Market Competitive Analysis

2.6.1 Prostate Cancer Diagnostics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Prostate Cancer Diagnostics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer Diagnostics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Tumor Biomarker Tests

3.1.2 Imaging

3.1.3 Biopsy

3.1.4 Other

3.2 Global Prostate Cancer Diagnostics Sales Value by Type

3.2.1 Global Prostate Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Prostate Cancer Diagnostics Sales Value, by Type (2019-2030)

3.2.3 Global Prostate Cancer Diagnostics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Age Below 55

4.1.2 Age 55-75

4.1.3 Age Above 75

4.2 Global Prostate Cancer Diagnostics Sales Value by Application

4.2.1 Global Prostate Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Prostate Cancer Diagnostics Sales Value, by Application (2019-2030)

4.2.3 Global Prostate Cancer Diagnostics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Prostate Cancer Diagnostics Sales Value by Region

5.1.1 Global Prostate Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Prostate Cancer Diagnostics Sales Value by Region (2019-2024)

5.1.3 Global Prostate Cancer Diagnostics Sales Value by Region (2025-2030)

5.1.4 Global Prostate Cancer Diagnostics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Prostate Cancer Diagnostics Sales Value, 2019-2030

5.2.2 North America Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Prostate Cancer Diagnostics Sales Value, 2019-2030

5.3.2 Europe Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Prostate Cancer Diagnostics Sales Value, 2019-2030

5.4.2 Asia Pacific Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Prostate Cancer Diagnostics Sales Value, 2019-2030

5.5.2 South America Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Prostate Cancer Diagnostics Sales Value, 2019-2030

5.6.2 Middle East & Africa Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Prostate Cancer Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Prostate Cancer Diagnostics Sales Value

6.3 United States

6.3.1 United States Prostate Cancer Diagnostics Sales Value, 2019-2030

6.3.2 United States Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Prostate Cancer Diagnostics Sales Value, 2019-2030

6.4.2 Europe Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Prostate Cancer Diagnostics Sales Value, 2019-2030

6.5.2 China Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Prostate Cancer Diagnostics Sales Value, 2019-2030

6.6.2 Japan Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Prostate Cancer Diagnostics Sales Value, 2019-2030

6.7.2 South Korea Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Prostate Cancer Diagnostics Sales Value, 2019-2030

6.8.2 Southeast Asia Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Prostate Cancer Diagnostics Sales Value, 2019-2030

6.9.2 India Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 OPKO

7.1.1 OPKO Profile

7.1.2 OPKO Main Business

7.1.3 OPKO Prostate Cancer Diagnostics Products, Services and Solutions

7.1.4 OPKO Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.1.5 OPKO Recent Developments

7.2 Genomic Health

7.2.1 Genomic Health Profile

7.2.2 Genomic Health Main Business

7.2.3 Genomic Health Prostate Cancer Diagnostics Products, Services and Solutions

7.2.4 Genomic Health Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.2.5 Genomic Health Recent Developments

7.3 Abbott

7.3.1 Abbott Profile

7.3.2 Abbott Main Business

7.3.3 Abbott Prostate Cancer Diagnostics Products, Services and Solutions

7.3.4 Abbott Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.3.5 Beckman Coulter Recent Developments

7.4 Beckman Coulter

7.4.1 Beckman Coulter Profile

7.4.2 Beckman Coulter Main Business

7.4.3 Beckman Coulter Prostate Cancer Diagnostics Products, Services and Solutions

7.4.4 Beckman Coulter Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.4.5 Beckman Coulter Recent Developments

7.5 Siemens Healthcare

7.5.1 Siemens Healthcare Profile

7.5.2 Siemens Healthcare Main Business

7.5.3 Siemens Healthcare Prostate Cancer Diagnostics Products, Services and Solutions

7.5.4 Siemens Healthcare Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.5.5 Siemens Healthcare Recent Developments

7.6 bioMeriux

7.6.1 bioMeriux Profile

7.6.2 bioMeriux Main Business

7.6.3 bioMeriux Prostate Cancer Diagnostics Products, Services and Solutions

7.6.4 bioMeriux Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.6.5 bioMeriux Recent Developments

7.7 Roche

7.7.1 Roche Profile

7.7.2 Roche Main Business

7.7.3 Roche Prostate Cancer Diagnostics Products, Services and Solutions

7.7.4 Roche Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.7.5 Roche Recent Developments

7.8 MDx Health

7.8.1 MDx Health Profile

7.8.2 MDx Health Main Business

7.8.3 MDx Health Prostate Cancer Diagnostics Products, Services and Solutions

7.8.4 MDx Health Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.8.5 MDx Health Recent Developments

7.9 DiaSorin

7.9.1 DiaSorin Profile

7.9.2 DiaSorin Main Business

7.9.3 DiaSorin Prostate Cancer Diagnostics Products, Services and Solutions

7.9.4 DiaSorin Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.9.5 DiaSorin Recent Developments

7.10 Myriad Genetics

7.10.1 Myriad Genetics Profile

7.10.2 Myriad Genetics Main Business

7.10.3 Myriad Genetics Prostate Cancer Diagnostics Products, Services and Solutions

7.10.4 Myriad Genetics Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.10.5 Myriad Genetics Recent Developments

7.11 Ambry Genetics

7.11.1 Ambry Genetics Profile

7.11.2 Ambry Genetics Main Business

7.11.3 Ambry Genetics Prostate Cancer Diagnostics Products, Services and Solutions

7.11.4 Ambry Genetics Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.11.5 Ambry Genetics Recent Developments

8 Industry Chain Analysis

8.1 Prostate Cancer Diagnostics Industrial Chain

8.2 Prostate Cancer Diagnostics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Prostate Cancer Diagnostics Sales Model

8.5.2 Sales Channel

8.5.3 Prostate Cancer Diagnostics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Prostate Cancer Diagnostics Market Trends

Table 2. Prostate Cancer Diagnostics Market Drivers & Opportunity

Table 3. Prostate Cancer Diagnostics Market Challenges

Table 4. Prostate Cancer Diagnostics Market Restraints

Table 5. Global Prostate Cancer Diagnostics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Prostate Cancer Diagnostics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Prostate Cancer Diagnostics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Prostate Cancer Diagnostics Product Type

Table 9. Key Companies Time to Begin Mass Production of Prostate Cancer Diagnostics

Table 10. Global Prostate Cancer Diagnostics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer Diagnostics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Prostate Cancer Diagnostics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Prostate Cancer Diagnostics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Prostate Cancer Diagnostics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Prostate Cancer Diagnostics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Prostate Cancer Diagnostics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Prostate Cancer Diagnostics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Prostate Cancer Diagnostics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Prostate Cancer Diagnostics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Prostate Cancer Diagnostics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Prostate Cancer Diagnostics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Prostate Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Prostate Cancer Diagnostics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Prostate Cancer Diagnostics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Prostate Cancer Diagnostics Sales Value by Region (2019-2024) & (%)

Table 27. Global Prostate Cancer Diagnostics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Prostate Cancer Diagnostics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Prostate Cancer Diagnostics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Prostate Cancer Diagnostics Sales Value, (2025-2030) & (US$ Million)

Table 31. OPKO Basic Information List

Table 32. OPKO Description and Business Overview

Table 33. OPKO Prostate Cancer Diagnostics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of OPKO (2019-2024)

Table 35. OPKO Recent Developments

Table 36. Genomic Health Basic Information List

Table 37. Genomic Health Description and Business Overview

Table 38. Genomic Health Prostate Cancer Diagnostics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of Genomic Health (2019-2024)

Table 40. Genomic Health Recent Developments

Table 41. Abbott Basic Information List

Table 42. Abbott Description and Business Overview

Table 43. Abbott Prostate Cancer Diagnostics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of Abbott (2019-2024)

Table 45. Abbott Recent Developments

Table 46. Beckman Coulter Basic Information List

Table 47. Beckman Coulter Description and Business Overview

Table 48. Beckman Coulter Prostate Cancer Diagnostics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of Beckman Coulter (2019-2024)

Table 50. Beckman Coulter Recent Developments

Table 51. Siemens Healthcare Basic Information List

Table 52. Siemens Healthcare Description and Business Overview

Table 53. Siemens Healthcare Prostate Cancer Diagnostics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of Siemens Healthcare (2019-2024)

Table 55. Siemens Healthcare Recent Developments

Table 56. bioMeriux Basic Information List

Table 57. bioMeriux Description and Business Overview

Table 58. bioMeriux Prostate Cancer Diagnostics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of bioMeriux (2019-2024)

Table 60. bioMeriux Recent Developments

Table 61. Roche Basic Information List

Table 62. Roche Description and Business Overview

Table 63. Roche Prostate Cancer Diagnostics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of Roche (2019-2024)

Table 65. Roche Recent Developments

Table 66. MDx Health Basic Information List

Table 67. MDx Health Description and Business Overview

Table 68. MDx Health Prostate Cancer Diagnostics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of MDx Health (2019-2024)

Table 70. MDx Health Recent Developments

Table 71. DiaSorin Basic Information List

Table 72. DiaSorin Description and Business Overview

Table 73. DiaSorin Prostate Cancer Diagnostics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of DiaSorin (2019-2024)

Table 75. DiaSorin Recent Developments

Table 76. Myriad Genetics Basic Information List

Table 77. Myriad Genetics Description and Business Overview

Table 78. Myriad Genetics Prostate Cancer Diagnostics Products, Services and Solutions

Table 79. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of Myriad Genetics (2019-2024)

Table 80. Myriad Genetics Recent Developments

Table 81. Ambry Genetics Basic Information List

Table 82. Ambry Genetics Description and Business Overview

Table 83. Ambry Genetics Prostate Cancer Diagnostics Products, Services and Solutions

Table 84. Revenue (US$ Million) in Prostate Cancer Diagnostics Business of Ambry Genetics (2019-2024)

Table 85. Ambry Genetics Recent Developments

Table 86. Key Raw Materials Lists

Table 87. Raw Materials Key Suppliers Lists

Table 88. Prostate Cancer Diagnostics Downstream Customers

Table 89. Prostate Cancer Diagnostics Distributors List

Table 90. Research Programs/Design for This Report

Table 91. Key Data Information from Secondary Sources

Table 92. Key Data Information from Primary Sources

Table 93. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Prostate Cancer Diagnostics Product Picture

Figure 2. Global Prostate Cancer Diagnostics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 4. Prostate Cancer Diagnostics Report Years Considered

Figure 5. Global Prostate Cancer Diagnostics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Prostate Cancer Diagnostics Revenue in 2023

Figure 7. Prostate Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Tumor Biomarker Tests Picture

Figure 9. Imaging Picture

Figure 10. Biopsy Picture

Figure 11. Other Picture

Figure 12. Global Prostate Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 13. Global Prostate Cancer Diagnostics Sales Value Market Share by Type, 2023 & 2030

Figure 14. Product Picture of Age Below 55

Figure 15. Product Picture of Age 55-75

Figure 16. Product Picture of Age Above 75

Figure 17. Global Prostate Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Prostate Cancer Diagnostics Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 20. North America Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 25. South America Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 26. South America Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions Prostate Cancer Diagnostics Sales Value (%), (2019-2030)

Figure 30. United States Prostate Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 32. United States Prostate Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe Prostate Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe Prostate Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 36. China Prostate Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 37. China Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 38. China Prostate Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan Prostate Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan Prostate Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea Prostate Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea Prostate Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia Prostate Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia Prostate Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 48. India Prostate Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 49. India Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 50. India Prostate Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 51. Prostate Cancer Diagnostics Industrial Chain

Figure 52. Prostate Cancer Diagnostics Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions